Details for Patent: 9,566,252
✉ Email this page to a colleague
Title: | Method for the alleviation of dyspareunia in women |
Abstract: | This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof. |
Inventor(s): | Halonen; Kaija (Rusko, FI), Kangas; Lauri (Lieto, FI), DeGregorio; Michael W. (Granite Bay, CA) |
Assignee: | HORMOS MEDICAL LTD. (Turku, FI) |
Filing Date: | Jul 15, 2010 |
Application Number: | 12/837,292 |
Claims: | 1. A method for alleviating dyspareunia during or after menopause, said method comprising administering to a woman in need thereof an effective amount of (deaminohydroxy)toremifene or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, wherein the (deaminohydroxy)toremifene is not a salt. 3. The method according to claim 1, wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered orally. 4. The method according to claim 2, wherein the (deaminohydroxy)toremifene is administered in a daily dose of 25 to 100 mg. 5. The method according to claim 2, wherein the (deaminohydroxy)toremifene is administered in a daily dose of 60 mg. 6. The method according to claim 5, wherein the (deaminohydroxy)toremifene is administered orally. 7. The method according to claim 1, wherein the woman is a postmenopausal woman. 8. The method according to claim 2, wherein the woman is a postmenopausal woman. 9. The method according to claim 6, wherein the woman is a postmenopausal woman. 10. The method according to claim 1, wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered in a daily dose of 30 to 90 mg. 11. The method according to claim 1, wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered in a daily dose of 60 mg. 12. The method according to claim 1, wherein the (deaminohydroxy)toremifene is administered orally in a daily dose of 60 mg. |